Eli Lilly

SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer

Retrieved on: 
Wednesday, January 3, 2024
Conference, Wills Eye Hospital, Biotechnology, Paratriathlon, Medicine, Nightstar, Acquisition, Eli Lilly, Alcon, Retina, ProQR, Drug, MD, Ocriplasmin, Merck & Co., Stargardt disease, Abstract, Protein splicing, Laboratory, Stargardt, Merck, Gene, Genetic, Growth, Biogen, Pharmaceutical industry

BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.

Key Points: 
  • BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.
  • Dr Girach was Global Head of Ophthalmology at Merck & Co and Vice President, Clinical Development at Alcon Laboratories.
  • Prior to joining SpliceBio, he led the development of genetic therapies for inherited retinal diseases at ProQR Therapeutics NV as its Chief Medical Officer.
  • Aniz Girach, MD., Chief Medical Officer of SpliceBio, commented: "Inherited retinal diseases are a heterogenous group of rare diseases that can lead to severe visual disability and blindness, affecting approximately 5.5 million people worldwide.

Pacira Appoints Frank D. Lee as Chief Executive Officer

Retrieved on: 
Thursday, December 21, 2023
Marketing, Roche, Immunology, Infection, Business, Chemical engineering, Eli Lilly, Vanderbilt University, Janssen, Acquisition, Chairperson, MBA, Therapy, Cancer, Novo Nordisk, Novartis, Engineering, Genentech, Growth, Patient, Senior, Management

TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the “Board”) has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. As previously announced in September 2023, David Stack will retire from his roles as Chief Executive Officer and Chairman of the Board, effective January 1, 2024, and will remain with the company through August 2025 in an advisory capacity to help ensure a smooth transition. In connection with Mr. Stack’s retirement, the Board has elected Paul Hastings, Lead Independent Director, as Chair of the Board, also effective January 2, 2024.

Key Points: 
  • TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the “Board”) has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024.
  • Most recently he served as Chief Executive Officer and member of the board of directors of Forma Therapeutics from March 2019 through its acquisition by Novo Nordisk in October 2022.
  • Prior to joining Genentech, Mr. Lee spent approximately 13 years across Novartis, Janssen and Eli Lilly in engineering, manufacturing, sales/marketing and business development.
  • On December 20, 2023, in connection with Mr. Lee’s appointment as Chief Executive Officer, the Board approved the grant of inducement awards to Mr. Lee.

Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations

Retrieved on: 
Tuesday, December 12, 2023
MBC, ESR1, Eli Lilly, Mutation, Gene, Poster, Patient, Safety, Therapy, Pharmaceutical industry

“Secondary analysis of our ELAINE study results reveals reassuring pharmacokinetic data, further confidence in lasofoxifene’s ability to be effectively combined with abemaciclib, and a better understanding of the baseline genomic alterations found in patients with ESR1 mutations,” said Dr. Paul Plourde, Sermonix vice president for clinical oncology development.

Key Points: 
  • “Secondary analysis of our ELAINE study results reveals reassuring pharmacokinetic data, further confidence in lasofoxifene’s ability to be effectively combined with abemaciclib, and a better understanding of the baseline genomic alterations found in patients with ESR1 mutations,” said Dr. Paul Plourde, Sermonix vice president for clinical oncology development.
  • Key takeaways included:
    PK data for lasofoxifene 5 mg/day were consistent with previous clinical trials, resulting in similar steady-state concentrations in patients across several studies.
  • A second poster discussed baseline genomic alterations and the activity of lasofoxifene and abemaciclib during the ELAINE-2 study.
  • Key results/conclusions included:
    In 26 of the 29 patients (median age 60 years) enrolled, ESR1 mutations were identified at baseline by the Guardant360® CDx test.

Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor

Retrieved on: 
Tuesday, December 12, 2023
RNA, Biotechnology, Research, Eli Lilly, Trustee, Therapy, Cancer, Eli Lilly and Company, Interim, Publication, Organization

The Company also announced that Thomas H. Jensen, co-founder and member of the Board of Directors of Allarity Therapeutics, has been appointed as Interim Chief Executive Officer.

Key Points: 
  • The Company also announced that Thomas H. Jensen, co-founder and member of the Board of Directors of Allarity Therapeutics, has been appointed as Interim Chief Executive Officer.
  • The Company has also engaged Jeremy R. Graff, Ph.D., as an Executive Advisor.
  • With his deep understanding of the Company’s mission, its team, and technology, we look forward to a smooth and successful leadership change.”
    Commenting on his appointment as Interim CEO, Thomas H. Jensen stated, “I am honored to take on the role of Interim CEO at Allarity Therapeutics.
  • Dr. Graff’s contributions to the field of oncology are underscored by his numerous publications, patents, and affiliations with esteemed organizations.

RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development

Retrieved on: 
Monday, December 11, 2023
Amylin Pharmaceuticals, Biotechnology, Sale, Eli Lilly, Strategic management, OTC Markets Group, Therapy, Business development, RespireRx, Decision Sciences, Dronabinol, Eli Lilly and Company

Mr. Clodfelter will initially lead the business development efforts with respect to dronabinol, the lead asset of ResolutionRx Ltd, a wholly-owned Australian subsidiary of the Company.

Key Points: 
  • Mr. Clodfelter will initially lead the business development efforts with respect to dronabinol, the lead asset of ResolutionRx Ltd, a wholly-owned Australian subsidiary of the Company.
  • Mr. Clodfelter will collaborate with Jeff Eliot Margolis, the Company’s Senior Vice President, Chief Financial Officer, Treasurer and Secretary in driving these efforts.
  • He previously held positions at Eli Lilly and Co. in Corporate Strategy and Business Development.
  • He was at Amylin Pharmaceuticals in New Product Planning and Decision Sciences and was involved in multiple business development activities.

Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology

Retrieved on: 
Monday, December 11, 2023
Editorial, Quality of life, ESR1, Hospital, ESMO, Medicine, ASCO, Woman, Breast cancer, Fulvestrant, Annals of Oncology, Eli Lilly, Breast, Business model, Progression-free survival, Massachusetts General Hospital, Congress, Society, Trial of the century, International Society, Mutation, Annual general meeting, Neoplasm, Oncology, Patient, PFS, Therapy, Pharmaceutical industry

Also, 30.7% of patients on lasofoxifene achieved a PFS of 12 months compared to 14.1% on fulvestrant.

Key Points: 
  • Also, 30.7% of patients on lasofoxifene achieved a PFS of 12 months compared to 14.1% on fulvestrant.
  • Results were initially shared at a poster discussion session during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and updated in June at ASCO 2023.
  • Annals of Oncology provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine.
  • To learn more about Sermonix Pharmaceuticals and lasofoxifene, visit SermonixPharma.com .

Yseop Announces Strategic Investment and Celebrates Milestone of 150 Clinical Trials Powered by Generative AI

Retrieved on: 
Thursday, December 7, 2023
Narrative, SCS, CSR, Partnership, Trial of the century, Synthetic media, FDA, Eli Lilly, Vaccine, Diabetes, Clinical trial, LLM, Writing, Patient, Acceleration, Automation, Neurology, History, Pharmaceutical industry

Included in these clinical trials are many of the most notable advancements in new treatments, vaccines, and medicines that society has seen in recent history.

Key Points: 
  • Included in these clinical trials are many of the most notable advancements in new treatments, vaccines, and medicines that society has seen in recent history.
  • By automating parts of the clinical document landscape, like the Clinical Study Report (CSR), Patient Narrative, and Summary Clinical Safety (SCS), Yseop is one of the first GenAI applications in production today for medical and regulatory writing.
  • In 2023 alone, Yseop generated 10,000+ reports and eliminated tens of thousands of hours of writing and review time.
  • Yseop and its Generative AI capabilities have already proven its value within pharma, actively deployed across multiple therapeutic areas, including vaccines, immunology, diabetes, oncology, neurology, and Rx (medical prescription).

Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers

Retrieved on: 
Thursday, November 30, 2023
Computer science and engineering, Marketing, Glooko, IP Group, Drug discovery, AstraZeneca, Eli Lilly, Business administration, Molecular biology, Annual general meeting, Retirement, Virology, Eli Lilly and Company, Therapy, American Red Cross, Head, Duke University, University, Obesity, Doctor of Philosophy, Mechanical, Management

20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company’s board of directors.

Key Points: 
  • 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company’s board of directors.
  • It is expected that Enrique Conterno and Elaine Sullivan will stand for election to Zealand Pharma’s board of directors at the company’s 2024 Annual General Meeting.
  • “As board observes, Enrique and Elaine collectively bring decades of international pharmaceutical industry experience to Zealand Pharma,” said Martin Nicklasson, Chairman of the board of directors.
  • From January 2020 until August 2023, Enrique Conterno served as the CEO and member of the board of directors at FibroGen, Inc.

Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Tuesday, November 28, 2023
Quality of life, MBC, ESR1, Eli Lilly, Life, Pharmacokinetics, Quality, Mutation, Abstract, Toxicity, Patient, Safety, Therapy, Communication

COLUMBUS, Ohio, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced that it had five abstracts accepted as poster presentations at the 2023 San Antonio Breast Cancer Symposium (SABCS), which will be held Dec. 5-9 at the Henry B. Gonzalez Convention Center in San Antonio.

Key Points: 
  • COLUMBUS, Ohio, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced that it had five abstracts accepted as poster presentations at the 2023 San Antonio Breast Cancer Symposium (SABCS), which will be held Dec. 5-9 at the Henry B. Gonzalez Convention Center in San Antonio.
  • Three posters delve into clinical data tied to Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) studies.
  • One assesses baseline genomic alterations and the activity of lasofoxifene, Sermonix’s investigational novel endocrine therapy, and Eli Lilly and Company’s CDK4/6 inhibitor abemaciclib during the ELAINE-2 study.
  • A second poster addresses pharmacokinetics of lasofoxifene as a monotherapy and in combination with abemaciclib.

858 Therapeutics Expands Leadership Team to Support Transition to the Clinic

Retrieved on: 
Wednesday, December 20, 2023
Other Health, Hospitals, Health, Clinical Trials, Oncology, Texas Lutheran University, Eli Lilly, DNA, Therapy, PARG, PARP, DNA repair, Death, Doctor of Philosophy, Patient, AbbVie, Pharmaceutical industry

858 Therapeutics is pleased to announce today that it has named Katherine Bell-McGuinn, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • 858 Therapeutics is pleased to announce today that it has named Katherine Bell-McGuinn, M.D., Ph.D., as Chief Medical Officer.
  • The addition of Dr. Bell-McGuinn strengthens the 858 Therapeutics leadership team as the company prepares to initiate clinical trials in 2024.
  • Dr. Bell-McGuinn brings extensive clinical development experience to 858 Therapeutics.
  • “We’re excited to welcome Kathy to the 858 Therapeutics leadership team.